GLSI Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of 17.96%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 55.13%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $57.30 which suggests that it could grow by 4.95%. Given that Greenwich LifeSciences, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Greenwich LifeSciences, Inc. is more attractive than Bristol Myers Squibb Co..

Greenwich LifeSciences, Inc. has a beta of 1.449, which suggesting that the stock is 44.943% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.215%.

Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.56% to investors and pays a quarterly dividend of $0.63 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -243.13%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.

Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 55.13%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $63.59 which suggests that it could grow by 334.35%. Given that Janux Therapeutics, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Greenwich LifeSciences, Inc..

Greenwich LifeSciences, Inc. has a beta of 1.449, which suggesting that the stock is 44.943% more volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend.

Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Janux Therapeutics, Inc. quarterly revenues of $10M. Greenwich LifeSciences, Inc.'s net income of -$4.2M is higher than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 88.77x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -19.69%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat Moderna, Inc.'s return on equity of -30.18%.

Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 55.13%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -21.44%. Given that Greenwich LifeSciences, Inc. has higher upside potential than Moderna, Inc., analysts believe Greenwich LifeSciences, Inc. is more attractive than Moderna, Inc..

Greenwich LifeSciences, Inc. has a beta of 1.449, which suggesting that the stock is 44.943% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than Moderna, Inc. quarterly revenues of $1B. Greenwich LifeSciences, Inc.'s net income of -$4.2M is higher than Moderna, Inc.'s net income of -$200M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 8.33x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

60 Degrees Pharmaceuticals, Inc. has a net margin of -- compared to Greenwich LifeSciences, Inc.'s net margin of -438.1%. Greenwich LifeSciences, Inc.'s return on equity of -781.94% beat 60 Degrees Pharmaceuticals, Inc.'s return on equity of -193.16%.

Greenwich LifeSciences, Inc. has a consensus price target of $47.50, signalling upside risk potential of 55.13%. On the other hand 60 Degrees Pharmaceuticals, Inc. has an analysts' consensus of $4.40 which suggests that it could grow by 263.64%. Given that 60 Degrees Pharmaceuticals, Inc. has higher upside potential than Greenwich LifeSciences, Inc., analysts believe 60 Degrees Pharmaceuticals, Inc. is more attractive than Greenwich LifeSciences, Inc..

Greenwich LifeSciences, Inc. has a beta of 1.449, which suggesting that the stock is 44.943% more volatile than S&P 500. In comparison 60 Degrees Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Greenwich LifeSciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 60 Degrees Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Greenwich LifeSciences, Inc. pays -- of its earnings as a dividend. 60 Degrees Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Greenwich LifeSciences, Inc. quarterly revenues are --, which are smaller than 60 Degrees Pharmaceuticals, Inc. quarterly revenues of $528.6K. Greenwich LifeSciences, Inc.'s net income of -$4.2M is lower than 60 Degrees Pharmaceuticals, Inc.'s net income of -$2.3M. Notably, Greenwich LifeSciences, Inc.'s price-to-earnings ratio is -- while 60 Degrees Pharmaceuticals, Inc.'s PE ratio is 15.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Greenwich LifeSciences, Inc. is -- versus 2.42x for 60 Degrees Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.